CA-CROSSFIT
At the conclusion of the 2020 Reebok CrossFit Games Open in October, CrossFit, Inc. will find the fittest man and woman in every eligible country participating in the worldwide CrossFit Open and crown them national champions. National champions automatically qualify for the 2020 Reebok CrossFit Games, held in August in Madison, Wisconsin. There, national champions will have the chance to compete with other Games athletes for $1.6M and the title of Fittest on Earth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191007005216/en/
What Are the CrossFit Games?
The CrossFit Games are a grueling, multi-day competition in which elite athletes, ages 14 to 60+, and teams from around the world compete in the ultimate test of fitness. The CrossFit Games are the Sport of Fitness, and well-rounded athletes train to be prepared for unknown events announced just before the competition. CrossFit movements are selected from gymnastics, powerlifting, Olympic lifting, running, rowing, and beyond.
Athletes arrive in Madison, Wisconsin, with almost no knowledge of the actual events, so their training has to cover a wider range of activities than any other professional sport. They are ranked during competition with their peers, and the winners are crowned Fittest on Earth after proving their fitness in a series of diverse events over the course of several days. The 2020 event will be the 13th annual edition of the CrossFit Games and the largest field of individual athletes ever. The total purse this year is more than $2.3M.
What Is the CrossFit Games Open?
The CrossFit Games Open is the largest fitness competition on Earth and the first of three competitions that form the CrossFit Games season: the Open, the Age Group Online Qualifier, and the Games. In the Open, hundreds of thousands of athletes from more than 15,000 CrossFit affiliates worldwide compete in a five-week test of fitness. This online competition is open to anyone in the world. Every week, from Oct. 10, 2019, to Nov. 11, 2019, athletes will complete a workout designed by CrossFit, Inc. to test cardiovascular/respiratory endurance, stamina, strength, flexibility, power, coordination, agility, balance, and accuracy.
Upon completion of the Open, the top 20 athletes worldwide, as well as the first-place male and female competitors from each eligible country, will earn invitations to compete at the 2020 Reebok CrossFit Games. Following the Open, top age group athletes from 14-17 and 35-60+ have a second online qualifier to earn an Age Group spot in the finals. Beyond these two online qualifiers, the only way for an athlete to guarantee a spot in the finals is to win one of the 28 Sanctionals™ (CrossFit competitions that are individually owned and operated).
CrossFit Games Open National Champions
The 2020 season will mark the second year in which CrossFit, Inc. awards the first-place man and woman in every eligible nation worldwide the opportunity to compete at the CrossFit Games.
In 2019, CrossFit crowned a total of 232 national champions hailing from 123 different countries. On Thursday, Aug. 1, 2019, the first day of competition in Madison, Wisconsin, 143 men and 117 women representing 114 countries took the field, becoming the most diverse field of athletes the CrossFit Games had ever seen.
From Afghanistan to Belgium, Egypt to Estonia, Kosovo to Kuwait — the National Champion Open qualifier gives athletes from nations where CrossFit is in its infancy the opportunity to evolve the sport and represent their countries on a worldwide stage.
There are virtually no barriers to entry for any athlete who wishes to represent their country at the 2020 Reebok CrossFit Games. No professional status or allegiance to a sport federation is required or even preferred. Athletes need only do the following:
- Register for the Open.
- Complete and video record all five Open workouts as prescribed over the course of the Open. Submit scores to games.crossfit.com.
Champions will be notified after the Leaderboard is set upon completion of the Open and after citizenship is verified.
About CrossFit, Inc.
CrossFit, Inc. is the developer and provider of the CrossFit® fitness program and a recognized worldwide leader in functional fitness. Founded by Greg Glassman and built on the foundations of constantly varied, high-intensity functional movements, education and collaborative competition, CrossFit-brand workouts develop strength and fitness while cultivating community and camaraderie in each of the more than 15,000 affiliated gyms in CrossFit’s global network. CrossFit, Inc. is a leading accredited certificate issuer for physical-training professionals worldwide and offers specialty certificate programs in addition to its core curriculum. CrossFit, Inc.’s health initiatives pursue an investigation into the ills of modern medicine and the willful abuse of the public’s trust in science. CrossFit, Inc. created and operates the CrossFit Games, an annual competition where elite athletes compete to be named the Fittest on Earth™. To learn more, visit www.CrossFit.com , Games.CrossFit.com , or http://www.youtube.com/CrossFitHQ.
CrossFit, Forging Elite Fitness, The Sport of Fitness and Fittest on Earth are registered trademarks or trademarks of CrossFit, Inc. in the U.S. and/or other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005216/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
